Evidence map›Paper›PMID 40957819›Full record

Trial reportJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2026

Evaluation of the drug interaction between rifabutin and elexacaftor/tezacaftor/ivacaftor (ETI).

Madeline Sanders, Eunjin Hong, Peter S Chung, Adupa P Rao, Whitaker Cohn, Paul Beringer

Registry-linked trialAbstract readClinical Trial, Phase IV
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04840862 (Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04840862 phase4completednot on this map

Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor

TypeinterventionalSponsorUniversity of Southern CaliforniaRan2022 to 2024Enrolled6ConditionsDrug Drug InteractionArmsTrikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg], Rifabutin 300mg
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Madeline SandersAlfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA.
Eunjin HongCollege of Pharmacy, Dongguk University, Seoul, South Korea.
Peter S ChungDivision of Pulmonary and Clinical Care Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Anton Yelchin CF Clinic, University of Southern California, Los Angeles, CA, USA.
Adupa P RaoDivision of Pulmonary and Clinical Care Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Anton Yelchin CF Clinic, University of Southern California, Los Angeles, CA, USA.
Whitaker CohnAlfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA.
Paul BeringerAlfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA; Anton Yelchin CF Clinic, University of Southern California, Los Angeles, CA, USA. Electronic address: beringer@usc.edu.

Funding

DOCTORAL AND POST-DOCTORAL TRAINING IN CRANIOFACIAL BIOLOGYT90DE021982 · NIDCR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI PAINE, MICHAEL LANSDELL · 2011 to 2025
$6.2M
NIDCR NIH HHS T90 DE021982
6 · The paper itself

Abstract

backgroundRifampin is a guideline-recommended treatment for nontuberculous mycobacteria infections; however, it is a strong inducer of CYP3A metabolism and therefore is contraindicated in patients receiving elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA; ETI). Rifabutin (RFB), a moderate CYP3A inducer, is a potential therapeutic alternative to rifampin. A prospective, single-arm study was conducted in healthy volunteers to evaluate the effect of RFB on ETI pharmacokinetics (PK) (NCT04840862, 2022-05-09).

methodsSix adults received a single dose of ETI (100 mg/50 mg/75 mg). After a washout, subjects received 2 weeks of RFB 300 mg daily followed by a second single ETI dose. The data were analyzed using noncompartmental PK.

resultsThe maximum plasma concentration (C

conclusionsRFB alters ETI PK, but to a lesser extent than rifampin. These data indicate that a clinical trial evaluating the efficacy and safety of ETI with concomitant rifabutin treatment is warranted.

Indexed as

AminophenolsBenzodioxolesCytochrome P-450 CYP3A InducersIndolesPyridinesPyrrolesQuinolonesRifabutinAdultDrug CombinationsDrug InteractionsFemaleHealthy VolunteersHumansMaleMiddle AgedAminophenolsBenzodioxolesCytochrome P-450 CYP3A InducersDrug CombinationselexacaftorIndolesPyrazolesPyridinesPyrrolesPyrrolidinesQuinolonesRifabutinRifampintezacaftor, ivacaftor drug combinationCYP3A4 inductionCystic fibrosisDrug-drug interactionsETIPharmacokineticsRifabutin

Identifiers

PMID40957819
PMCPMC12576919

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.